Introduction
The clinical relevance of autonomous cortisol secretion (ACS) in pa tients with adrenal incidentalomas has been widely recognized in the last years. This condition has usually been defined in patients with alteration of hormonal values, including a combination of ele vated cortisol after dexamethasone suppression test, reduced ACTH, or high urinary free cortisol or latenight cortisol, in the ab sence of a clear phenotype of Cushing's syndrome. Until 2016, different diagnostic criteria have been used in several studies pub lished in the last 20 years, generating difficulties in the interpreta tion of the comorbidities associated with mild hypercortisolism [1] .
Eventually, the recent guidelines published in 2016 have clarified several aspects of diagnosis and management of patients with ad renal incidentalomas and ACS, pointing toward the central role of dexamethasone suppression test (DST) as a diagnostic tool [1] . ACS is defined by cortisol levels after DST > 1.8 µg/dL (possible) or > 5 µg/dL (confirmed) in patients with adrenal incidentalomas with out catabolic signs of Cushing's syndrome. Several studies have clearly shown that a mild and persistent cortisol hypersecretion is associated with harmful clinical consequences. However, several uncertainties remain on the identification of patient at elevated risk who may benefit from targeted treatments. The aim of this re view is to evaluate the current evidence on the main clinicallyrel Patients with adrenal incidentalomas and autonomous cortisol secretion (ACS) have been recognized as a category at risk of developing cardiovascular and metabolic comorbidities. Con sidering the increasing number of patients affected by this condition, it is important to perform an accurate subtyping of the patients, in the light of a tailored treatment. This review aims to identify the phenotypic characteristics of patients with adrenal incidentalomas and ACS who are at risk of developing severe cortisolrelated comorbidities. ACS has been associ ated with severe alteration of the cardiovascular profile, includ ing hypertension, diabetes, and atherosclerosis. Moreover, ACS has been identified as a contributing factor to the development of cardiovascular events and related mortality. Patients with ACS are also at risk of incident bone fractures, which occur in half of the patients independently of the bone mass density, and infectious diseases. Severity and persistence of hypercor tisolism are among the main contributing factors for cardio vascular diseases and bone fractures. Moreover, progression of hypercortisolism over time and altered circadian cortisol rhythm seem to be important additional factors. The role of potential novel biomarkers is also discussed in this review. evant outcomes associated with ACS, to identify the clinical and biochemical picture of patients at elevated risk of cardiovascular and metabolic diseases.
Clinically Relevant Outcomes in Adrenal Incidentalomas

Risk of cardiovascular diseases
During the last 20 years, increasing evidence from crosssectional studies showed that patients with adrenal tumors associated with ACS have an impaired cardiovascular profile, as highlighted by the high prevalence of several cardiovascular risk factors, mainly hy pertension and diabetes. The link between hypertension and mild cortisol excess has been established in several studies, as shown in a recent review of the literature [2] . Even though a precise calcula tion of the prevalence of hypertension among patient with ACS is cumbersome, due to the low comparability among the different methods of the studies, hypertension is by far the most frequent cortisolrelated comorbidity found in patients with ACS. Indeed, the prevalence of hypertension in patients with ACS is over 60 % in 2/3 of the studies published in the last 15 years [2] . Moreover, pa tients with ACS seems to be more prone to develop resistant hy pertension, as defined by treatment with more than three antihy pertensive medications. Studies investigating the prevalence of ACS among hypertensive patients have shown that excessive cor tisol secretion may be found in a negligible number of subjects with essential hypertension (1 %) [3] . However, a study analyzing only patients with resistant hypertension showed that 8 % of hyperten sive patients had biochemical evidence of cortisol excess, as de fined by cortisol after DST > 1.8 µg/dL and two confirmed records of elevated midnight salivary cortisol levels [4] . It is worth mention ing that among 423 patients included in the initial cohort, 112 (26.5 %) had cortisol values after DST > 1.8 µg/dL with or without additional alterations of the hypothalamic pituitary adrenal axis, a condition that it now recognized as possible autonomous cortisol secretion, in keeping with the current guidelines on adrenal inci dentalomas [1] .
In addition to hypertension, several markers of subclinical ath erosclerosis have been studied in patients with ACS. Among them, higher values of intima-media thickness (IMT) and lower flow-me diated dilation (FMD) have been reported in crosssectional evi dence, in patients with ACS, when compared to nonfunctioning tumors [5] [6] [7] . The association between altered IMT and severity of hypercortisolism has been recently investigated in a metaanalysis of 14 studies that characterized the cardiovascular risk of patients with Cushing's syndrome. IMT, FMD, and atherosclerotic plaques were independently associated with severity and duration of cor tisol excess, as shown in patients with active disease [8] . Moreover, improvement of IMT was correlated with the median time of dis ease remission in cured patients, providing indirect evidence on the role of duration of cortisol excess as an important determinant of the development of subclinical atherosclerosis [8] . Instead, the association between markers of subclinical atherosclerosis and ACS is not yet completely understood, as shown by a few studies pro viding contrasting results. The lack of agreement among the dif ferent studies is mainly due to the different parameters that were selected as markers of cortisol hypersecretion, like urinary free cor tisol or midnight cortisol, which are frequently within the normal range in patients with ACS. Nonetheless, the association between ACS and increased IMT seems to be a relevant issue only in older patients [5] . Several studies shed light on the potential association between altered markers of subclinical atherosclerotic and non functioning adrenal incidentalomas (reviewed in [9] ). Even with the limitation due to the crosssectional design, those studies raise the question whether steroids other than cortisol may have a role in impairing the cardio-metabolic profile of patients with adrenal in cidentalomas. Indeed, retrospective evidence showed that patients bearing nonfunctioning adrenal incidentalomas have a higher in cidence of diabetes in a longterm setting [10] .
Thrombotic diathesis is a wellknown consequence of Cushing's syndrome. Thromboembolic events have been identified as an im portant causative factor for cardiovascular events, together with hypertension, in up to 20 % of the patients [11] . Even though fewer studies have investigated the hypercoagulable state in patients with ACS, alteration of several parameters (protein C, free protein S, thrombomodulin, and alpha1 antitrypsin) resembling that of Cushing's syndrome have been reported in patients with subclini cal cortisol hypersecretion [12] .
Longterm retrospective studies shed light on the association be tween cardiovascular events and excessive cortisol production in pa tients with adrenal incidentalomas. Three independent studies pub lished in 2014 showed that the incidence of myocardial infarction and stroke was indeed higher than that of nonfunctioning tumors [13] [14] [15] . As shown by Cox regression models, the incidence of car diovascular events was associated with increasing values of cortisol secretion over time, giving feed to the hypothesis that the progres sion of hypercortisolism may be an important contributing factor for development cardiovascular events [13] . Interestingly, among the potential contributing factors, previous cardiovascular events, absence of lipid lowering treatment, and hypertension were inde pendent contributors to the incidence of cardiovascular events [13] . Similarly, allcause and cardiovascularrelated mortality were also increased in patients with ACS, with respect to nonfunctioning tu mors [13] and to the general population [15] . Therefore, cortisol levels and their progression over time seem to have a relevant role in determining cardiovascular events in patients with adrenal inci dentalomas. However, the cortisolrelated mechanisms (direct ef fects of cortisol on cardiovascular system vs indirect actions through the associated comorbidities) leading to the cardiovas cular damage are still not completely understood. It is important to notice that among cardiovascular diseases, the myocardial in farction is more prevalent over stroke in patients with ACS [16] . Recent evidence highlighted that cardiac performance may be al tered in patients with hypercortisolism, adding interesting and novel features to the cardiovascular profile of patients with ACS. A recent crosssectional analysis of a large cohort of patients with in cidentalomas revealed that left ventricular mass index, a marker of cardiac hypertrophy associated with hypertension, and pulse wave velocity, a marker of arterial stiffness, were significantly higher in patients with ACS [17] . Moreover, concentric and eccentric left ven tricular hypertrophy was more prevalent in patients with ACS. No tably, those alterations occurred independently of the presence and duration of hypertension, and the number of hypertensive drugs, which were not different between patients with non-func tioning tumors and those with ACS. Those direct and surrogate markers of altered cardiac performance were independently asso ciated with cortisol levels after DST [17] .
Another interesting aspect of the relationship between cardio vascular diseases and ACS is related to two distinct features of hy percortisolism, the severity and the progression of cortisol hyper secretion. As previously mentioned, the occurrence of cardiovas cular diseases is independently predicted by the increasing severity of hypercortisolism over time [13] . Additionally, allcause mortal ity, with cardiovascular diseases as the most frequent cause, was associated with the mean of cortisol after DST during followup, uncovering the importance of the persistence of hypercortisolism over time [13] . The role of cortisol as a risk factor for mortality in ACS has been confirmed by the observation that patients belong ing to three different classes of increasing severity of hypercorti solism (cortisol after DST < 1.8 µg/dL, between 1.8 and 5 µg/dL and > 5 µg/dL, respectively) are at parallel increased risk of allcause and cardiovascularrelated mortality [15] .
Additionally, the alteration of the circadian cortisol rhythm has been recognized as a potential contributing factor for the develop ment of cardiovascular events. Evidence from populationbased studies and targeted investigations revealed that flattening of di urnal cortisol rhythm is associated with increased cardiovascular related mortality in the general population and a higher incidence of adverse cardiovascular events in patients undergoing coronary artery bypass graft surgery [18, 19] . Less is known about the alter ations of the circadian cortisol rhythm in patients with ACS. This issue has been investigated in a few studies, providing contrasting results, mainly due to the different definition of ACS, the different sampling conditions (inpatients for serum cortisol vs outpatients for salivary cortisol), and the different assays for cortisol (immuno metric assays vs mass spectrometrybased measurements). A re cent crosssectional study by Ceccato et al. provided the results of the analysis of the circadian salivary cortisol measured by mass spectrometry in 106 patients with adrenal incidentalomas [20] . Patients with cortisol levels after DST > 1.8 µg/dL showed a higher area under the curve (AUC) for salivary cortisol in morning meas urements and throughout the day, than those with nonfunction ing tumors. The difference in the AUC was mainly due to signifi cantly increased levels of cortisol in the morning. No difference was detected in evening and latenight cortisol levels between the two groups. Even though this study points toward a higher morning cortisol exposure in patients with cortisol after DST > 1.8 µg/dL, no subgroups analysis for morning ACTH levels nor analysis of the as sociation between cortisol exposure and clinical correlates have been performed. Apart from AUC, more informative analyses have been proposed as integrated measurements of circadian rhythmic ity, such as cosinor analysys [21] , deconvolution parameters and approximate entropy [22] . However, none of those parameters have been applied to the study of adrenal incidentalomas. The role of circadian cortisol rhythm disruption as a potential marker of se verity of hypercortisolism in adrenal incidentalomas is still under investigation. It may be speculated that the altered cortisol rhythm may identify a subgroup of patients at higher risk of comorbidi ties. Indeed, in a recent proof of concept study, Debono et al. in vestigated the potential implications of the restoration of a normal circadian cortisol rhythm in patients with incidentalomas, by using a steroidogenesis inhibitor [23] . Among six patients with increased evening cortisol levels, administration of Metyrapone 500 mg at 6 P.M. and 250 mg at 10 P.M. was able to reassess the cortisol rhythm. This effect was associated with a parallel normalization of IL-6 levels, a known inflammatory marker associated with cardio vascular risk and endothelial disfunction. Larger prospective stud ies are strongly needed to investigate the clinical impact of such a targeted treatment in a longterm run.
An important, still unresolved, issue is the impact of cosecre tion of aldosterone and steroid precursors in patients with ACS and the implication for cardiovascular diseases. A recent study investi gating the 24h urinary output of steroid metabolites by mass spec trometry pointed toward a prevalent glucocorticoid excess in pa tients with primary aldosteronism in a nonnegligible proportion of patients [24] . The cosecretion was highlighted biochemically, by the increased levels of several glucocorticoid precursors in urine samples, and clinically, by the onset of adrenal insufficiency after surgery. In a recent case series, the immunohistochemical analysis of five tumors associated with ACS and concomitant primary aldo steronism revealed that those tumors were mainly composed by zona fasciculatalike cells, with a heterogeneous expression of CYP11B1 and CYP11B2 [25] . A recent study investigating the serum steroid profiling by mass spectrometry in patients with different subtypes of Cushing's syndrome showed increased levels of 11de oxycortisol and 11deoxycorticosterone in adrenaldependent hy percortisolism, when compared to controls [26] . Those alterations were not associated with a parallel increase in aldosterone, giving feed to the hypothesis that those steroid precursors may be pro duced mainly by fasciculata cells. Additionally, an earlier pilot study published in 2015, showed a hyperresponsiveness of several ster oid precursors under 124 ACTH stimulation in patients with uni lateral adrenal adenomas associated with ACS [27] . The potential pejorative impact of the cosecretion of other steroids in associa tion with cortisol on the cardiovascular system of patients with ACS is an open topic and deserves further investigation.
Risk of bone fractures
Despite the wellknown association between steroid excess and bone fracture risk in patients taking exogenous glucocorticoids, a few studies have been performed in patients with endogenous hy percortisolism. Indeed, endogenous and exogenous glucocorti coid-induced osteoporosis represent two different models of dis eases, in terms of severity and duration of cortisol exposure. The mechanisms of glucocorticoidinduced osteoporosis are beyond the scopes of this review and are summarized in a recent paper [28] .
The appropriateness of the assessment of bone fractures risk in patients with hypercortisolism by evaluation of bone mass density (BMD) has been largely questioned. Indeed, cortisolrelated bone fractures have mainly been associated with altered bone quality and occur independently of the BMD [29] . The occurrence of oste oporosis has been described in 28-50 % of patients with overt Cush ing's syndrome [30] , whereas vertebral fractures have been report ed in a variable proportion of patients with hypercortisolism (21-76 %) [31, 32] . Such a wide range is mainly due to the study design and the different methods of assessment of vertebral fractures (retrospective evaluations vs targeted investigation by radiological images). Notably, the prevalence of asymptomatic ver tebral fractures among patients with endogenous hypercortisolism was 48 % [31] . Fewer studies have investigated the association be tween ACS and bone fractures. According to a recent metanalysis, the prevalence of vertebral fractures has been estimated in 64 % (95 % confidence interval -CI 56-71 %) [29] . Similarly, the incidence of vertebral fractures during followup has been recognized as a major issue, occurring in 48 % of the patients [29] . Among other known risk factors, the increased incidence of new vertebral frac tures was associated with the presence of ACS (odd ratio 12, 95 % CI 4-37), defined by the presence of at least two alterations among cortisol after DST > 3 µg/dL, increased urinary free cortisol levels, and ACTH levels < 10 pg/ml [33] .
Considering the limitations of using the BMD as a predictor of vertebral fractures in patients with Cushing's syndrome, and that the major problem of cortisolinduced osteoporosis is qualitative rather than quantitative, several techniques have been studied to investigate the bone quality in patients with hypercortisolism. Spi nal deformity index (SDI) and trabecular bone score (TBS) have been used frequently, because of their feasibility and relative low cost. SDI is a semiquantitative method that integrates number and se verity of bone fractures as a surrogate marker of bone quality [34] . TBS is a greylevel texture measurement calculated from the 2di mensional images of the dual energy Xray absorptiometry (DEXA) scans at the lumbar level, which gives information about the micro architecture of the bone [35] . Patients with ACS showed higher SDI than nonfunctioning adrenal tumors, in crosssectional and pro spective settings [33, 36] . The application of TBS to the study of pa tients with adrenal incidentalomas revealed that ACS is character ized by lower TBS values than those of patients with nonfunction ing adrenal tumors and control subjects. Moreover, TBS was associated with occurrence of vertebral fractures and cortisol levels, independently of other potential contributing factors [37] . Inter estingly, TBS was also associated with the incidence of new verte bral fractures over a 2year period, independently of the BMD [37] . A recent large cross-sectional study has confirmed the superiority of TBS over BMD in the evaluation of bone fragility in patients with various degree of hypercortisolism, including ACS and Cushing's syndrome of different etiologies. Patients with ACS showed lower TBS values (1.3 ± 0.1), when compared to patients with nonfunc tioning adrenal tumors (1.4 ± 0.1) (P < 0.04), regardless of BMD [38] .
Bone fractures in patients with hypercortisolism have been as sociated with either exposure and duration of cortisol hypersecre tion [39] . Even though the excessive cortisol production undoubt edly plays a pivotal role in this context [28] , the involvement of ad ditional factors associated with hypercortisolism in increasing the risk of fractures, like sarcopenia, as a potential risk of fall, is still under investigation. Indeed, patients with hypercortisolism are characterized by severely altered muscle mass and performance, which is correlated with severity of hypercortisolism, as shown by radiological and clinical evidence [40, 41] . Even though the differ ences were clearer for overt Cushing's syndrome, a reduced mus cle mass was also detected in patients with ACS, who do not have clinical stigmata of sarcopenia. A thorough evaluation of muscle performance in patients with ACS is still lacking to date. Recent ev idence highlighted that some degrees of altered protein metabo lism may feature the biochemical phenotype of patients with ACS, with several disturbances of amino acid metabolism, including re duction of histidine, proline, and kynurenine levels [42] . Those al terations have been found in patients with overt Cushing's syn drome and in patients with ACS and were associated with the se verity of hypercortisolism [42] . Considering the role of histidine and proline as component of collagen matrix, it may be speculated that their alteration may have a potential impact on muscle strength and sarcopenia. To further support the muscular implica tion of ACS, a recent report on a small cohort of patients showed that women affected by ACS had a significant reduction in muscle mass than those with nonfunctioning tumors, as assessed by bio electrical impedance analysis [43] . Additionally, the role of reduced androgens has been identified as an important determinant of re duced muscle mass, which is a wellknown cortisolrelated clinical consequence [44] . Several reports have highlighted that patients with either Cushing's syndrome or ACS have lower levels of DHEA and androstenedione than subjects bearing nonfunctioning tu mors and controls, independently of age [26, 27] . The relationship between sarcopenia, androgens, and risk of fall has been highlight ed in a very recent large populationbased studies, showing that lower DHEA and DHEAsulphate were associated with increased in cidence of falls [45] .
A thorough evaluation of muscle performance and its relation ship with reduced androgens in patients with ACS deserves further evaluation.
Risk of infectious diseases
Infectious diseases are a known complication of hypercortisolism. A recent populationbased cohort study showed that patients with overt Cushing's syndrome are at increased risk of mortality due to infections, with hazard ratio of 4.9 (95 % CI 3.76.4) [46] . The in creased mortality rate was associated with cortisol secretion inde pendently of the specific subtypes of Cushing's syndrome and per sisted elevated for several years after treatment [46] . The cortisol related mechanisms underlying immune system disruption are still not completely understood. Direct and indirect effects of cortisol, through immunosuppression, vascular damage, and hyperglyce mia are among the most frequent causes of susceptibility to infec tions of patients with Cushing's syndrome. A summary on the mo lecular mechanisms driving alterations in immune response in hy percortisolism has been recently published elsewhere [11] . Apart from the severity of hypercortisolism, altered circadian cortisol rhythm seems to play a significant role in the alteration of the im mune response, mainly by disruption of the circadian lymphocyte rhythm. This concept has been highlighted in a recent randomized controlled trial, showing that restoration of a pseudophysiologi cal circadian rhythmicity of cortisol improved the immune cell pro file of patients with adrenal insufficiency [47] . Specifically, patients receiving modified-release hydrocortisone tabs showed a reduc tion in the number of proinflammatory monocytes CD14( + ) CD16(), lowering their susceptibility to infections [47] .
The relevance of infectious complications in patients with ACS has been underestimated and rarely investigated until recently. A longterm retrospective study on the natural history of ACS, previ ously mentioned, revealed that the infectious complication was the second cause of mortality in patients with ACS, after cardiovascular diseases [15] . Moreover, the prevalence of infections was higher than that of the general population. This was the first study high lighting the clinical impact of prolonged, although mild, hypercor tisolism on the immune system in the longterm run. Moreover, the reduction in IL6 levels after restoration of cortisol rhythm by Metyrapone pointed toward a possible link between altered circa dian rhythmicity and infectious complications [23] . Further confir mation is awaited from targeted studies.
The Identification of High-Risk Patients
A summary of the risk factors for clinical outcomes in patients with ACS is depicted in ▶ Fig. 1 . Considering the clinical picture of ACS, it is feasible to speculate about the potential phenotype of patients at risk of developing clinicallyrelevant outcomes. Cortisol levels after DST > 1.8 µg/dL may be considered as a reliable cut-off to iden tify a subgroup of patients with adrenal incidentalomas who are at risk of developing cardiovascular events, provided that the meas urement is confirmed over time. Moreover, increasing levels of cor tisol after DST during subsequent controls should be interpreted as an additional risk factor for cardiovascular diseases. The cortisol related risk seems to be an independent contributor to cardiovas cular events, mainly in patients with altered cardiovascular profile. The main implication of this hypothesis is that patients with adre nal incidentalomas presenting with hypertension, dyslipidemia, and previous cardiovascular events should be considered for cor tisol-lowering treatments, if affected by ACS, or addressed to a careful hormonal followup to rule out progression of cortisol se cretion, if bearing a nonsecreting tumor. Whether cosecretion of additional steroids and altered circadian cortisol rhythm are pejo rative factors is unknown to date.
Conversely, the risk of incident bone fractures seems to be rel evant in patients with cortisol levels after DST at a higher cut point (i. e. > 3 µg/dL) and additional hormonal alterations, such as re duced ACTH levels and elevated urinary cortisol. It is feasible that a more severe hormonal profile may be necessary for the develop ment of bone fragility. Even though additional factors like de creased androgens and sarcopenia seem to contribute to the risk of fractures, stronger evidence is needed. Overall, the occurrence of asymptomatic vertebral fractures has been recorded in half of the patients with ACS. Therefore, a fracture risk assessment should be recommended in all patients with ACS by morphometric evalu ation of the spine and assessment of surrogate markers of bone fragility (e. g. SDI or TBS).
The phenotypic characterization of patients at risk of infectious diseases is cumbersome. Given that patients with disrupted circa dian rhythm seem to be prone to develop infectious complications, a careful examination of daily cortisol profiles may be useful in all patients with ACS. However, it is important mentioning that the impact of infectious diseases on the wellbeing of patients with ACS is still under investigation.
Conclusion
Patients with adrenal incidentalomas are a category at potential risk of lifethreatening conditions. Due to the considerable num ber of patients affected by this condition, a careful characterization of the subtypes of patients at risk is essential to avoid unnecessary examinations in lowrisk patients, on one side, and underestima tion of the potential comorbidities in highrisk patients, on the other side. Even though some phenotypic characteristics may be helpful in identifying patients at risk, further studies should be per formed to identify specific biomarkers for risk assessment and sub typing of the patients, in the light of a tailored and costsaving management of patients with adrenal incidentalomas.
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